Barrett’s Esophagus in 2012: Updates in Pathogenesis, Treatment, and Surveillance
GI ONCOLOGY (R BRESALIER, SECTION EDITOR)
First Online: 19 April 2013 DOI:
10.1007/s11894-013-0322-8 Cite this article as: Chandra, S., Gorospe, E.C., Leggett, C.L. et al. Curr Gastroenterol Rep (2013) 15: 322. doi:10.1007/s11894-013-0322-8 Part of the following topical collections: Topical Collection on GI Oncology Abstract
Barrett’s esophagus (BE) is the only established precursor lesion in the development of esophageal adenocarcinoma (EAC) and it increases the risk of cancer by 11-fold. It is regarded as a complication of gastroesophageal reflux disease. There is an ever-increasing body of knowledge on the pathogenesis, diagnosis, treatment, and surveillance of BE and its associated dysplasia. In this review, we summarize the latest advances in BE research and clinical practice in the past 2 years. It is critical to understand the molecular underpinnings of this disorder to comprehend the clinical outcomes of the disease. For clinical gastroenterologists, there is also continuous growth of endoscopic approaches which is daunting, and further improvements in the detection and treatment of BE and early EAC are anticipated. In the future, we may see the increased role of biomarkers, both molecular and imaging, in both diagnostic and therapeutic strategies for BE.
Keywords Barrett’s esophagus Esophageal adenocarcinoma Biomarkers Acid reflux Obesity Endoscopic mucosal resection Radiofrequency ablation Photodynamic therapy Cryotherapy Narrow band imaging Confocal laser endomicroscopy Optical coherence tomography
This article is part of the Topical Collection on
GI Oncology References Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Wang KK. Endoscopic vs surgical resection for Barrett’s intramucosal adenocarcinoma: beyond a therapeutic equipoise. Gastroenterology. 2012;143(1):257–9.
Peters FP, Curvers WL, Rosmolen WD, et al. Surveillance history of endoscopically treated patients with early Barrett’s neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus. 2008;21(6):475–9.
Prasad GA, Wang KK, Halling KC, et al. Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer. 2008;113(3):470–6.
Sarosi G, Brown G, Jaiswal K, et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett’s esophagus. Dis Esophagus. 2008;21(1):43–50.
Hutchinson L, Stenstrom B, Chen D, et al. Human Barrett’s adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant. Stem Cells Dev. 2011;20(1):11–7.
Bianchi NO. Y chromosome structural and functional changes in human malignant diseases. Mutat Res. 2009;682(1):21–7.
Orlando RC. Pathophysiology of gastroesophageal reflux disease. J Clin Gastroenterol. 2008;42(5):584–8.
Souza RF, Huo X, Mittal V, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009;137(5):1776–84.
Yoshida N, Imamoto E, Uchiyama K, et al. Molecular mechanisms involved in interleukin-8 production by normal human oesophageal epithelial cells. Aliment Pharmacol Ther Symp Ser. 2006;2(1):219–26.
Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJ. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut. 2002;50(4):451–9.
Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140(3):1084–91.
Rubenstein JH, Saini SD, Kuhn L, et al. Influence of malpractice history on the practice of screening and surveillance for Barrett’s esophagus. Am J Gastroenterol. 2008;103(4):842–9.
•• Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83.
This is a landmark population based study of the incidence rate of esophageal cancer in the Danish population. The study establishes that the incidence is less than a third of previously established rate.
Burnat G, Majka J, Konturek PC. Bile acids are multifunctional modulators of the Barrett’s carcinogenesis. J Physiol Pharmacol Off J Polish Physiol Soc. 2010;61(2):185–92.
Huo X, Juergens S, Zhang X, et al. Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-kappaB activation in benign Barrett’s epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011;301(2):G278–86.
McQuaid KR, Laine L, Fennerty MB, Souza R, Spechler SJ. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther. 2011;34(2):146–65.
Schiffman SC, Li Y, Xiao D, Li X, Aiyer HS, Martin RC. The resistance of esophageal adenocarcinoma to bile salt insult is associated with manganese superoxide dismutase expression. J Surg Res. 2011;171(2):623–30.
Iijima K, Henry E, Moriya A, Wirz A, Kelman AW, McColl KE. Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology. 2002;122(5):1248–57.
Kusaka G, Uno K, Iijima K, et al. The role of nitric oxide in the induction of caudal-type homeobox 2 through epidermal growth factor receptor in the development of Barrett’s esophagus. Scand J Gastroenterol 2012.
Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547–94.
Paz-Filho G, Lim EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. Front Biosci J Virtual Libr. 2011;16:1634–50.
Howard JM, Beddy P, Ennis D, Keogan M, Pidgeon GP, Reynolds JV. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg. 2010;97(7):1020–7.
Leggett C, Calvin AD, Gorospe EC, et al. Obstructive sleep apnea is a risk factor for Barrett’s esophagus. Gastroenterology. 2012;142(5):S751–2.
Cook MB, Shaheen NJ, Anderson LA, et al. Cigarette smoking increases risk of Barrett’s esophagus: an analysis of the Barrett’s and esophageal adenocarcinoma consortium. Gastroenterology. 2012;142(4):744–53.
Jacobson BC, Giovannucci EL, Fuchs CS. Smoking and Barrett’s esophagus in women who undergo upper endoscopy. Dig Dis Sci. 2011;56(6):1707–17.
Coleman HG, Bhat S, Johnston BT, McManus D, Gavin AT, Murray LJ. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett’s esophagus. Gastroenterology. 2012;142(2):233–40.
Shariff MK, Bird-Lieberman EL, O’Donovan M, et al. Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett’s esophagus. Gastrointest Endosc. 2012;75(5):954–61.
Peery AF, Hoppo T, Garman KS, et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc. 2012;75(5):945–53. e942.
Kadri SR, Lao-Sirieix P, O’Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.
• Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G. Health Benefits and Cost Effectiveness of Endoscopic and Nonendoscopic Cytosponge Screening for Barrett’s Esophagus. Gastroenterology. 2012.
Screening for Barrett's esophagus is not cost effective if done with endoscopy. This cost-effectiveness study demonstrates that a non-physician based technique like the cytosponge, screening may be worthwhile.
Mino-Kenudson M, Hull MJ, Brown I, et al. EMR for Barrett’s esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc. 2007;66(4):660–6. quiz 767, 769.
Pech O, Bollschweiler E, Manner H, Leers J, Ell C, Holscher AH. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett’s esophagus at two high-volume centers. Ann Surg. 2011;254(1):67–72.
van Vilsteren FG, Pouw RE, Herrero LA, et al. Learning to perform endoscopic resection of esophageal neoplasia is associated with significant complications even within a structured training program. Endoscopy. 2012;44(1):4–12.
Alvarez Herrero L, Pouw RE, van Vilsteren FG, et al. Safety and efficacy of multiband mucosectomy in 1060 resections in Barrett’s esophagus. Endoscopy. 2011;43(3):177–83.
Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360(22):2277–88.
Yoon SS, Rivera R, Antignano L, Kaul V. A case of mediastinitis after radiofrequency ablation for Barrett’s esophagus. Gastrointest Endosc. 2011;74(6):1407–8.
Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141(2):460–8.
Okoro NI, Tomizawa Y, Dunagan KT, Lutzke LS, Wang KK, Prasad GA. Safety of prior endoscopic mucosal resection in patients receiving radiofrequency ablation of Barrett’s esophagus. Clin Gastroenterol Hepatol. 2012;10(2):150–4.
Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42(10):781–9.
• Gupta M, Lutzke LS, Prasad GA, et al. Recurrence of intestinal metaplasia after eradication of Barrett’s esophagus with radio frequency ablation - results from a BETRNet consortium. Gastroenterology. 2012;142(5):S73.
This large multicenter study of patients undergoing radiofrequency ablation found a substantial recurrence rate of intestinal metaplasia after ablation highlighting the need for surveillance after complete ablation.
Shaheen NJ, Greenwald BD, Peery AF, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 2010;71(4):680–5.
Greenwald BD, Dumot JA, Horwhat JD, Lightdale CJ, Abrams JA. Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esophagus. Dis Esophagus. 2010;23(1):13–9.
Canto MI, Gorospe EC, Shin EJ, Dunbar KB, Montgomery EA, Okolo P. Carbon Dioxide (CO2) cryotherapy is a safe and effective treatment of Barrett’s Esophagus (BE) with HGD/Intramucosal Carcinoma. Gastrointest Endosc. 2009;69(5):AB341.
Gross S, Zfass A, Habr F, et al. Salvage cryotherapy for Barrett’s esophagus with high grade dysplasia after RFA failure. Am J Gastroenterol. 2010;105:S23–4.
Flores AG, Reicher S, Chung DS, Pham BV, Eysselein VE. Barrett’s esophagus eradication by radiofrequency and cryoablation. Gastrointest Endosc. 2009;69(5):AB256.
Gorospe EC, Timmer MR, Lutzke L, Wang KK. Cryotherapy for persistent Barrett’s dysplasia after radiofrequency ablation. The American Journal of Gastroenterology. 2012, 107(S1).
Hirst NG, Gordon LG, Whiteman DC, Watson DI, Barendregt JJ. Is endoscopic surveillance for non-dysplastic Barrett’s esophagus cost-effective? Review of economic evaluations. J Gastroenterol Hepatol. 2011;26(2):247–54.
Gorospe EC, Wang KK. Endoscopy: NBI in Barrett esophagus–look more and sample less. Nat Rev Gastroenterol Hepatol. 2012;9(5):250–1.
Curvers WL, Herrero LA, Wallace MB, et al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett’s esophagus. Gastroenterology. 2010;139(4):1106–14.
Sharma P, Meining AR, Coron E, et al. Real-time increased detection of neoplastic tissue in Barrett’s esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc. 2011;74(3):465–72.
Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96(10):2839–48.
Jin Z, Cheng Y, Gu W, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res. 2009;69(10):4112–5.
Bird-Lieberman EL, Dunn JM, Coleman HG
, et al. Population-Based Study Reveals New Risk-Stratification Biomarker Panel for Barrett’s Esophagus. Gastroenterology 2012.
Lee S, Han MJ, Lee KS, et al. Frequent occurrence of mitochondrial DNA mutations in Barrett’s metaplasia without the presence of dysplasia. PLoS One. 2012;7(5):e37571.
Tan BH, Skipworth RJ, Stephens NA, et al. Frequency of the mitochondrial DNA 4977 bp deletion in oesophageal mucosa during the progression of Barrett’s oesophagus. Eur J Cancer. 2009;45(5):736–40.
Takata Y, Kristal AR, Santella RM, et al. Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett’s esophagus: results from biomarkers and genetic variants. PLoS One. 2012;7(6):e38612.
Gorospe EC TJ, Lutzke L, Brankley S, Halling K, Wang KK. Physician Satisfaction with Current Barrett’s Esophagus Surveillance and Acceptability of FISH-based Testing: A Survey of Gastroenterologists across the United States. In:
DDW 2012, vol. 142. San Diego, CA; 2012: S-73.
Quante M, Bhagat G, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell. 2012;21(1):36–51.
PubMed CrossRef Copyright information
© Springer Science+Business Media New York 2013